Reliable demand estimation is an essential input to many types of research in Industrial Organization and other fields of economics.
This paper presents a discussion of foundational issues: https://t.co/9NOsoIRiqE
@steventberry@PhilHaile
Randomized control trials are increasingly being used by cities to test innovations before scaling them.
But little is known about how these results are incorporated into policy making.
Here’s what @sdellavi, Woojin Kim, & @ElizabethLinos found.
https://t.co/m2aQN62VfM
Don't want to wait years to estimate the long-term effects of an intervention? A new method to estimate long-term impacts more rapidly and precisely by combining short-term proxies, from @Susan_Athey, @oppinsights, Guido W. Imbens, and Hyunseung Kang https://t.co/0k25jePnk5
NEWS: The FDA is approving a record number of generic drugs. Many aren't actually launching into the market. Our story helps explain why: https://t.co/zDqGmUVtNP
#EUAntitrust We've published the non-confidential version of our decision to fine Google for illegal practices regarding Android mobile devices 👉 https://t.co/RqhZjVb4hX
People say they love hard workers but they really love natural talent–a bias with troubling implications when it comes to hiring. https://t.co/efzQoDLNhK
How ‘Stealth’ Consolidation is Undermining Competition | @WSJ reports on rising corporate concentration citing a case study by @ChicagoBooth's Thomas Wollmann on kidney dialysis center acquisitions. https://t.co/AUNn87FVEp
THREAD
1/5 - There's a new trend in antitrust law: the demand for the creation of rules applicable to all, taken on the basis of micro-practices committed by a few. Hipster antitrusters do that well.
The #FDA has published the De Novo Classification Proposed Rule, which would establish procedures and criteria for the De Novo classification process and become part of the Medical Device Classification Procedures, via @virtualgr@Forbes https://t.co/KaZ5NECfB3